Guys Hospital

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions

• Lung cancer5 trials
• Colorectal cancer4 trials
• Ovarian cancer3 trials
• Atopic dermatitis (eczema)2 trials
• Melanoma2 trials
• Myeloproliferative neoplasms2 trials
• Prostate cancer2 trials
• Cervical cancer1 trial
• Childhood cancers1 trial
• COPD1 trial
• Coronary artery disease1 trial
• Endometrial cancer1 trial
• and 7 more

Phase

• Phase 315 trials
• Phase 27 trials
• Phase 12 trials
• Phase 1/22 trials

Status

• Active, not recruiting9 trials
• Completed7 trials
• Recruiting7 trials
• Terminated4 trials

Lead sponsor

• Amgen9 trials
• Incyte Corporation7 trials
• Hoffmann-La Roche2 trials
• Genentech, Inc.1 trial
• Imperial College London1 trial
• and 7 more

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

  NCT06804811· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Amgen· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Amgen· Source

• Active, not recruiting

  Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

  NCT06117774· Phase 3· Amgen· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

  NCT05968326· Phase 2· Genentech, Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

  NCT05926765· Phase 2· MeiraGTx, LLC· Source

• Active, not recruiting

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· Phase 3· Amgen· Source

• Active, not recruiting

  Study of INCB123667 in Subjects With Advanced Solid Tumors

  NCT05238922· Phase 1· Incyte Corporation· Source

• Recruiting

  A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT05085028· Phase 3· Imperial College London· Source

  Contact: James Spicer

• Recruiting

  A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

  NCT05037760· Phase 2· Takeda· Source

  Contact: Jennifer O'Sullivan (principal investigator)

• Active, not recruiting

  Atrasentan in Patients With IgA Nephropathy

  NCT04573478· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

  NCT03456076· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

  NCT03564340· Phase 1/2· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• Endometrial cancer1 recruiting
• Lung cancer1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Phase 3· Incyte Corporation· Source

• Terminated

  A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

  NCT05949632· Phase 1/2· Incyte Corporation· Source

• Terminated

  A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

  NCT06039384· Phase 1· Incyte Corporation· Source

• Terminated

  Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

  NCT04854096· Phase 2· NS Pharma, Inc.· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Amgen· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Phase 2· Incyte Corporation· Source

• Completed

  Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

  NCT04068181· Phase 2· Amgen· Source

• Completed

  A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer

  NCT03981146· Phase 2· University of Birmingham· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

  NCT02910557· Amgen· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Pfizer· Source